Key facts
- It has raised $39.4M; the latest was Later Stage VC ($20.0M) in Jan 2026.
- Notable investors include State of Maryland, Johns Hopkins Technology Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for CraniUS Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for CraniUS Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CraniUS Therapeutics
Developer of a multi-product drug delivery platform designed to bypass the blood-brain barrier for direct and targeted brain treatment. The company offers an implantable drug delivery system embedded within the skull, enabling pharmaceutical organizations and patients with neurological disorders to deliver therapies directly to the brain and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2021
- Employees
- 35
- Website
- craniustherapeutics.com/
- Ownership
- Privately Held (backing)
CraniUS Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CraniUS Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CraniUS Therapeutics in its N-PORT filings yet. We sweep new filings monthly.